ITGAE and Mobius syndrome: No changes were observed in any of the evaluated cell types, which included DC (CD11c hi) and myeloid cells (CD11b+), as well as specific cellular subsets of DC (CD11c hi CD11b+ and CD11c hi CD103+) and other myeloid subsets (macrophages: CD11b+ F4/80+, monocytic myeloid cells: CD11b+ Ly6C hi, and granulocytic myeloid cells: CD11b+ Ly6C mid) in FUS+MBs treated tumors two days and four days post treatment (Figure S2).